Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Gross Profit: 2020-2025

Historic Gross Profit for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $434.0 million.

  • Apellis Pharmaceuticals' Gross Profit rose 165.84% to $434.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.0 million, marking a year-over-year increase of 46.02%. This contributed to the annual value of $663.6 million for FY2024, which is 96.30% up from last year.
  • Apellis Pharmaceuticals' Gross Profit amounted to $434.0 million in Q3 2025, which was up 163.27% from $164.9 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Gross Profit high stood at $434.0 million for Q3 2025, and its period low was -$4.2 million during Q1 2021.
  • Its 3-year average for Gross Profit is $157.6 million, with a median of $152.1 million in 2024.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 75.90% in 2021, then skyrocketed by 2,506.74% in 2022.
  • Apellis Pharmaceuticals' Gross Profit (Quarterly) stood at $60.2 million in 2021, then crashed by 67.23% to $19.7 million in 2022, then skyrocketed by 540.72% to $126.5 million in 2023, then soared by 35.75% to $171.7 million in 2024, then spiked by 165.84% to $434.0 million in 2025.
  • Its Gross Profit stands at $434.0 million for Q3 2025, versus $164.9 million for Q2 2025 and $132.4 million for Q1 2025.